Everest Medicines Reports Promising Outcomes from Phase 1b/2a Study of Innovative BTK Inhibitor, EVER001 for Primary Membranous Nephropathy Treatment
Everest Medicines, a biopharmaceutical company committed to pioneering the discovery, development, production, and commercialization of novel therapies, has shared promising outcomes from their ongoing phase 1b/2a trial evaluating EVER001 for primary membranous nephropathy (pMN). A cutting-edge covalent reversible Bruton’s tyrosine […]